Table 9 Promoter CpG dinucleotide methylation of different genes in CML patients and association with different clinical stages
Gene | Stage of disease | Unmethylated n(%) | Methylated n(%) | Chi-Square | p-value |
|---|---|---|---|---|---|
RASSF1 | CP-CML | 94(94%) | 6 (6%) | 25.87 |  < 0.0001 |
AP-CML | 17(68%) | 8(32%) | |||
BC-CML | 14 (56%) | 11(44%) | |||
SOCS1 | CP-CML | 94 (94%) | 6 (6%) | 2.95 | 0.23 |
AP-CML | 22(88%) | 3(12%) | |||
BC-CML | 21(84%) | 4(16%) | |||
DAPK1 | CP-CML | 71(71%) | 29(29%) | 11.67 | 0.003 |
AP-CML | 13 (52%) | 12(48%) | |||
BC-CML | 9 (36%) | 16(64%) | |||
RIZ1 | CP-CML | 93 (93%) | 7(7%) | 6.40 | 0.04 |
AP-CML | 21(84%) | 4(16%) | |||
BC-CML | 19 (76%) | 6(24%) | |||
P16INK4A | CP-CML | 79(79%) | 21(21%) | 18.23 | 0.0001 |
AP-CML | 15(60%) | 10(40%) | |||
BC-CML | 9(36%) | 16(64%) | |||
P14ARF | CP-CML | 94(94%) | 6(6%) | 10.98 | 0.004 |
AP-CML | 18(72%) | 7(28%) | |||
BC-CML | 20(80%) | 5(20%) |